Co-occurring mutations in the POLE exonuclease and non-exonuclease domains define a unique subset of highly mutagenic tumors.
S. S. Shah, E. V. Demidova, S. Ringenbach, B. Faezov, M. Andrake, P. Mur, J. Viana-Errasti, J. Xiu, J. Swensen, L. Valle, R. Dunbrack, M. J. Hall, S. Arora
The paper identifies co-occurring POLE mutations in both exonuclease and non-exonuclease domains as a novel driver of ultra-high tumor mutation burden in certain cancers.
bioRxiv · Dec 15, 2022 · PreprintCancer Biology